CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects

S A Ivanova; M L Filipenko; N M Vyalova; E N Voronina; I V Pozhidaev; D Z Osmanova; M V Ivanov; O Yu Fedorenko; A V Semke; N A Bokhan

doi:10.1007/s10517-016-3250-4

CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects

Bull Exp Biol Med. 2016 Mar;160(5):687-90. doi: 10.1007/s10517-016-3250-4. Epub 2016 Mar 29.

Authors

S A Ivanova^{1

2}, M L Filipenko³, N M Vyalova⁴, E N Voronina³, I V Pozhidaev^{4

5}, D Z Osmanova^{4

5}, M V Ivanov⁶, O Yu Fedorenko^{4

7}, A V Semke⁴, N A Bokhan^{4

5}

Affiliations

¹ Research Institute of Mental Health, Tomsk, Russia. svetlana@mail.tomsknet.ru.
² National Research Tomsk Polytechnical University, Tomsk, Russia. svetlana@mail.tomsknet.ru.
³ Institute of Chemical Biology and Basic Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
⁴ Research Institute of Mental Health, Tomsk, Russia.
⁵ National Research Tomsk State University, Tomsk, Russia.
⁶ St. Petersburg V. M. Bekhterev Psychoneurological Research Institute, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
⁷ National Research Tomsk Polytechnical University, Tomsk, Russia.

PMID: 27021090
DOI: 10.1007/s10517-016-3250-4

Abstract

Polymorphic variants of CYP1A2 and CYP2D6 genes of the cytochrome P450 system were studied in patients with schizophrenia with drug-induced motor disorders and hyperprolactinemia against the background of long-term neuroleptic therapy. We revealed an association of polymorphic variant C-163A CYP1A2*1F of CYP1A2 gene with tardive dyskinesia and association of polymorphic variant 1846G>A CY2D6*4 and genotype A/A of CYP2D6 gene (responsible for debrisoquin-4-hydroxylase synthesis) with limbotruncal tardive dyskinesia in patients with schizophrenia receiving neuroleptics for a long time.

Keywords: Cytochromes; gene polymorphism; hyperprolactinemia; schizophrenia; tardive dyskinesia.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antipsychotic Agents / adverse effects*
Cytochrome P-450 CYP1A2 / genetics*
Cytochrome P-450 CYP2D6 / genetics*
Drug-Related Side Effects and Adverse Reactions / genetics
Female
Genetic Predisposition to Disease
Humans
Hyperprolactinemia / chemically induced*
Hyperprolactinemia / genetics
Male
Motor Disorders / chemically induced*
Motor Disorders / genetics
Polymorphism, Single Nucleotide / genetics
Schizophrenia / drug therapy*
Tardive Dyskinesia / chemically induced*
Tardive Dyskinesia / genetics

Substances

Antipsychotic Agents
Cytochrome P-450 CYP1A2
Cytochrome P-450 CYP2D6